SOURCE: VIVALIS

December 05, 2007 11:53 ET

Vivalis Announces the Grant of a Patent in Europe in Its Core Field of Avian Embryonic Stem Cells Thus Strengthening Its Intellectual Property Portfolio

NANTES, FRANCE--(Marketwire - December 5, 2007) - VIVALIS announced today that the European Patent Office (E.P.O) has granted a new European patent to VIVALIS under N degreesEP1446004. This patent protects, among others, a process of obtaining avian embryonic stem cells (ES) modified through homologous recombination to express recombinant proteins of interest.

This new patent strengthens the company's already solid portfolio of patents in the area of avian stem cells. This portfolio is composed of 3 exclusive world patent licences, two from North Carolina State University (USA) and one from the INRA/CNRS/ENS in Lyon (France), and 37 proprietary patents or patent applications. It is one of these patent applications that the E.P.O. has just officially granted in Europe.

FRANCK GRIMAUD, President of the VIVALIS Board of Directors, stated, "VIVALIS is delighted to have obtained this new patent. This will allow the company to continue to strengthen its intellectual property portfolio and consolidate its position as world leader in the field of avian stem cells."



*******************

Next calendar:

February 15th, 2008 after Euronext closing: Year 2007 Revenues

*******************

About VIVALIS (www.vivalis.com)

Vivalis (NYSE- Euronext: VLS) is a public biopharmaceutical company that provides innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and develops vaccines and drugs to prevent and treat viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants research & commercial licences to its proprietary ebx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody production systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary ebx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti-viral molecules.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Eurolist Paris - Sector B - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

This information is provided by HUGIN

Contact Information

  • Investor Relations:

    VIVALIS
    Franck Grimaud, C.E.O
    Email : Email Contact

    NEWCAP
    Financial Communication Agency
    Steve Grobet / Emmanuel Huynh
    Tel. : +33 (0) 1 44 71 94 91
    Email : Email Contact